MedicineOncologyPharmacologyBiochemical PharmacologyCancer PharmacologyChemotherapyAnthracycline CardiotoxicityCancer Therapy-related CardiotoxicityCardiac MedicationsCardiac PharmacotherapyPharmacodynamics Of Anticancer AgentsPharmacodynamics Of Anticancer DrugsAnthracycline-induced CardiotoxicityBiochemical CharacterizationCardiotoxicityCellular Damage MechanismsChemotherapy Dose-limiting ToxicityDose-limiting Cardiac ToxicityMechanisms Of Cardiac InjuryMechanisms Of Cellular Toxicity
Anthracyclines play an important role in treatment of variety types of cancer due to their high effectiveness and broad spectrum of activity. However, a major limitation of their use is the dose-limiting cardiotoxicity. The inability to predict and prevent anthracycline cardiotoxicity is in part due to the fact that the molecular and cellular mechanisms remain controversial and incompletely understood. This review focuses on the biochemical basis of the anthracyclines toxic cardiac effects and pharmacological measures to their treatment and preventing. We describe the theoretical substantiation of the enterosorption abilities for diminishing of cardiac damage.
48
Truncations of Titin Causing Dilated Cardiomyopathy
Daniel S. Herman, Lien Lam, Matthew R.G. Taylor et al. · New England Journal of Medicine · 2012 · 1.5K citations
The anthracyclines: will we ever find a better doxorubicin?
PubMed · 1992 · 559 citations
Medicine, Oncology, Pharmacology +16
Steven E. Lipshultz, Rebecca E. Scully, Stuart R. Lipsitz et al. · The Lancet Oncology · 2010 · 447 citations
Medicine, Pediatrics, Pharmacology +16